BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
5762 results:

  • 1. Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines.
    Kim BR; Kim DY; Tran NL; Kim BG; Lee SI; Kang SH; Min BY; Hur W; Oh SC
    Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757343
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Acute Myeloid leukemia with Myelodysplasia - Related Changes after Isolated Myeloid Sarcoma.
    Li X; Yin J; Li L
    Clin Lab; 2024 May; 70(5):. PubMed ID: 38747915
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
    Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
    Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis.
    Hu Z; Yang Y; Li J; Hu Z
    Hematology; 2024 Dec; 29(1):2346965. PubMed ID: 38687637
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
    Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
    Elife; 2024 Apr; 12():. PubMed ID: 38682900
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Cytogenetic abnormalities and tp53 and RAS gene profiles of childhood acute lymphoblastic leukemia in Morocco.
    Skhoun H; El Fessikh M; El Alaoui Al Abdallaoui M; Khattab M; Belkhayat A; Chebihi ZT; Hassani A; Abilkassem R; Agadr A; Dakka N; El Baghdadi J
    Arch Pediatr; 2024 May; 31(4):238-244. PubMed ID: 38679547
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Putting the STING back into BH3-mimetic drugs for tp53-mutant blood cancers.
    Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
    Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.
    Karel D; Valburg C; Woddor N; Nava VE; Aggarwal A
    Curr Oncol; 2024 Apr; 31(4):1971-1993. PubMed ID: 38668051
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
    Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Cortese M; Cripe L; Davis RS; Eradat H; Fakhri B; Fletcher CD; Gaballa S; Hamid MS; Hill B; Kaesberg P; Kahl B; Kamdar M; Kipps TJ; Ma S; Mosse C; Nakhoda S; Parikh S; Schorr A; Schuster S; Seshadri M; Siddiqi T; Stephens DM; Thompson M; Ujjani C; Valdez R; Wagner-Johnston N; Woyach JA; Sundar H; Dwyer M
    J Natl Compr Canc Netw; 2024 Apr; 22(3):175-204. PubMed ID: 38626800
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic leukemia.
    Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
    Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells.
    Alsulays BB; Aodah AH; Ahmed MM; Anwer MK
    Int J Nanomedicine; 2024; 19():3461-3473. PubMed ID: 38617799
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
    Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
    Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
    Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
    Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Decoding the tumour-modulatory roles of LIMK2.
    Chong ZX; Ho WY; Yeap SK
    Life Sci; 2024 Jun; 347():122609. PubMed ID: 38580197
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Unlocking the potential: A novel prognostic index signature for acute myeloid leukemia.
    Zhang LQ; Liang YC; Wang JX; Zhang J; La T; Li QZ
    Comput Biol Med; 2024 May; 173():108396. PubMed ID: 38574529
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
    Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
    Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia].
    Yuan XL; Wu YB; Song XL; Chen Y; Lu Y; Lai XY; Shi JM; Liu LZ; Zhao YM; Yu J; Yang LX; Lan JP; Cai Z; Huang H; Luo Y
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):41-47. PubMed ID: 38527837
    [No Abstract]    [Full Text] [Related]  

  • 18. Astaxanthin targets IL-6 and alleviates the LPS-induced adverse inflammatory response of macrophages.
    Wu Y; Bashir MA; Shao C; Wang H; Zhu J; Huang Q
    Food Funct; 2024 Apr; 15(8):4207-4222. PubMed ID: 38512055
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
    Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
    Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Azacitidine combined with venetoclax alleviates AML-MR with tp53 mutation in SDS: a case report and literature review.
    Ma C; Lang H; Chen Y; Yang L; Wang C; Han L; Chen X; Ma W
    Anticancer Drugs; 2024 Jul; 35(6):548-555. PubMed ID: 38502829
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 289.